Accord Healthcare
Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to more than 70 countries globally.
ADVERSE DRUG
REACTION
REPORT
Falsified Medicines Directive
Click Here
GROWTH’S IN OUR NATURE
Accord Healthcare is one of the fastest growing generic pharmaceutical companies in the UK & Ireland.
Acquiring Actavis UK and Ireland in 2017 facilitates Accord’s ambition to become a top 5 pan-EMENA generics company by 2021 and have developed a specialty products commercialisation capability.
TRULY MULTINATIONAL
Accord has one of the most extensive sales, marketing and distribution networks in Europe. Headquartered from UK, Accord now supplies products to close to 65 EMENA markets.
A COMPLETE APPROACH
Accord’s vision is to be involved in all aspects of bringing pharmaceuticals to patients. Our activities today encompass the entire pharmaceutical value chain and so create a truly integrated offering.
EUROPEAN FOCUS
Accord currently has a portfolio comprising nearly 7000 product approvals in Europe. We operate a pan European commercial footprint with direct presence in all major EU markets.
News
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Taipei, Taiwan and Harrow, England, February 11, 2019 – An exclusive license agreement for the commercialisation of Foresee Pharmaceutical’s (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accord Healthcare.
The Falsified Medicines Directive – Sandra Lee’s interview published in Pharmacy Business – February 2019 edition
Sandra Lee, Managing Director of Operations, explains why FMD is important and how the industry is preparing.